Soluble fms-like tyrosine kinase-1 expression inhibits the growth of multiple myeloma in nude mice

Acta Biochimica et Biophysica Sinica

Volumn 39, Issue 7, 2007, Pages 499-506

  Liu, Junru ^a   Li, Juan ^a   Su, Chang ^a   Huang, Beihui ^a   Luo, Shaokai ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Adenovirus; Gene therapy; Multiple myeloma; Receptor; Vascular endothelial growth factor

Indexed keywords

FLT1 PROTEIN, MOUSE; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BIOSYNTHESIS; CELL LINE; ENZYMOLOGY; FEMALE; GENE THERAPY; GENETICS; HUMAN; MOUSE; MULTIPLE MYELOMA; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE; VALIDATION STUDY;

ANIMALS; CELL LINE; CELL LINE, TUMOR; FEMALE; GENE THERAPY; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

ADENOVIRIDAE; MUS; MUS MUSCULUS;

EID: 34547142109     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1111/j.1745-7270.2007.00310.x     Document Type: Article

References (26)

1. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996, 335 : 91 97
2. Attal M, Harousseau JL, Leyvraz S, Doyen C, Hulin C, Benboubker L, Agha IY et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006, 108 : 3289 3294
3. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999, 341 : 1565 1571
4. Yakoub-Agha I, Attal M, Dumontet C, Delannoy V, Moreau P, Berthou C, Lamy T et al. Thalidomide in patients with advanced multiple myeloma: A study of 83 patients-report of the Intergroupe Francophone du Myelome (IFM). Hematol J 2002, 3 : 185 192
5. Folkman J. What is the evidence that tumors are angiogenesis dependent J Natl Cancer Inst 1990, 82 : 4 6
6. Ribas C, Colleoni GW, Silva MR, Carregoza MJ, Bordin JO. Prognostic significance of vascular endothelial growth factor immunoexpression in the context of adverse standard prognostic factors in multiple myeloma. Eur J Haematol 2004, 73 : 311 317
7. Kumar S, Witzig TE, Timm M, Haug J, Wellik L, Fonseca R, Greipp PR et al. Expression of VEGF and its receptors by myeloma cells. Leukemia 2003, 17 : 2025 2031
8. Usnarska-Zubkiewicz L, Mazur G, Wrobel T, Poreba M, Kuliczkowski K. Expression of serum vascular endothelial growth factor correlates with clinical outcome in multiple myeloma. Pol Arch Med Wewn 2003, 110 : 719 724
9. Vacca A, Ribatti D, Presta M, Minischetti M, Iurlaro M, Ria R, Albini A et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999, 93 : 3064 3073
10. Sezer O, Niemoller K, Eucker J, Jakob C, Kaufmann O, Zavrski I, Dietel M et al. Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma. Ann Hematol 2000, 79 : 574 577
11. Shibuya M, Yamaguchi S, Yamane A, Ikeda T, Tojo A, Matsushime H, Sato M. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 1990, 5 : 519 524
12. Wrobel T, Mazur G, Surowiak P, Dziegiel P, Usnarska-Zubkiewicz L, Kuliczkowski K. Increased expression of vascular endothelial growth factor in bone marrow of multiple myeloma patients. Eur J Intern Med 2003, 14 : 98 100
13. Bellamy WT, Richter L, Frutiger Y, Grogan TM. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 1999, 59 : 728 733
14. Podar K, Catley LP, Tai YT, Shringarpure R, Carvalho P, Hayashi T, Burger R et al. GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment. Blood 2004, 103 : 3474 3479
15. Lin B, Podar K, Gupta D, Tai YT, Li S, Weller E, Hideshima T et al. The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res 2002, 62 : 5019 5026
16. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci 1993, 90 : 10705 10709
17. Barleon B, Totzke F, Herzog C, Blanke S, Kremmer E, Siemeister G, Marme D et al. Mapping of the sites for ligand binding and receptor dimerization at the extracellular domain of the vascular endothelial growth factor receptor FLT-1. J Biol Chem 1997, 272 : 10382 10388
18. Kendall RL, Wang G, Thomas KA. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 1996, 226 : 324 328
19. Ye C, Feng C, Wang S, Wang KZ, Huang N, Liu X, Lin Y et al. sFlt-1 gene therapy of follicular thyroid carcinoma. Endocrinology 2004, 145 : 817 822
20. Mahasreshti PJ, Navarro JG, Kataram M, Wang MH, Carey D, Siegal GP, Barnes MN et al. Adenovirus-mediated soluble FLT-1 gene therapy for ovarian carcinoma. Clin Cancer Res 2001, 7 : 2057 2066
21. Hoshida T, Sunamura M, Duda DG, Egawa S, Miyazaki S, Shineha R, Hamada H et al. Gene therapy for pancreatic cancer using an adenovirus vector encoding soluble Flt-1 vascular endothelial growth factor receptor. Pancreas 2002, 25 : 111 121
22. Hasumi Y, Mizukami H, Urabe M, Kohno T, Takeuchi K, Kume A, Momoeda M et al. Soluble FLT-1 expression suppresses carcinomatous ascites in nude mice bearing ovarian cancer. Cancer Res 2002, 62 : 2019 2023
23. Podar K, Anderson KC. The pathophysiologic role of VEGF in hematologic malignancies: Therapeutic implications. Blood 2004, 105 : 1383 1395
24. Mahasreshti PJ, Kataram M, Wang MH, Stockard CR, Grizzle WE, Carey D, Siegal GP et al. Intravenous delivery of adenovirus-mediated soluble FLT-1 results in liver toxicity. Clin Cancer Res 2003, 9 : 2701 2710
25. Kuo CJ, Farnebo F, Yu EY, Christofferson R, Swearingen RA, Carter R, von Recum HA et al. Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc Natl Acad Sci 2001, 98 : 4605 4610
26. Podar K, Tonon G, Sattler M, Tai YT, Legouill S, Yasui H, Ishitsuka K et al. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc Natl Acad Sci 2006, 103 : 19478 19483